14 results about "Ebv infection" patented technology

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

This invention belongs to the field of antibody technology and discloses a monoclonal antibody that recognizes the Epstein-Barr virus (EBV) gp350 protein and its applications. This invention provides a monoclonal antibody against the EBV gp350 protein or its antigen-binding fragment, comprising 1A12 and 2E4, wherein 1A12 has a high affinity for the gp350 protein (KD(M) = 3.415E). ‑10 ), 2E4 has a high affinity for gp350 protein (KD(M) = 4.851E). ‑9 These two monoclonal antibodies or their antigen-binding fragments can significantly inhibit EBV infection of epithelial cells and B cells. They can be used to detect the presence or level of gp350 protein in samples, detect EBV, diagnose diseases caused by EBV infection, prevent EBV infection and / or treat and / or prevent diseases caused by EBV infection.

The present disclosure relates to nucleic acid molecules (e.g., self-replicating RNAs (srRNAs) expressing one or more antigenic determinants derived from Epstein-Barr virus (EBV)), recombinant cells containing the nucleic acid molecules and pharmaceutical compositions, and uses of such srRNA molecules, recombinant cells and compositions for eliciting pharmacodynamic effects in a subject. Methods for preventing and / or treating a variety of health conditions associated with EBV infection are also provided.

This invention provides EBV-susceptible 293T cells that simultaneously express the epidermal cell receptor EphA2 and the key protein RTA for lysis and replication, and EBV-susceptible BJAB cells that simultaneously express the B cell receptor CD21 and the key protein ZTA for lysis and replication, significantly enhancing the infectivity of these cells for EBV. The EBV infection titer of the cell lines of this invention is more than three times that of the normal control under the same conditions. These EBV-susceptible cells are of great significance for studying the mechanism of EBV infection, screening antiviral drugs, and developing vaccines.

The invention discloses a probe for detecting EBV infected tissue, a kit and a detection method, and belongs to the technical field of virus detection, the key point of the technical scheme is that the probe for detecting the EBV infected tissue is an EBER-PNA probe, the sequence number is GCGACACATGTCTGC, the EBER-specific target probe and EBER in cells are hybridized, flow cytometry is combined, and the EBER-PNA probe can be used for detecting the EBV infected tissue. The kit is high in specificity, low in background and high in signal-to-noise ratio, the detection method is simple and accurate, EBER RNA expression and protein of the same cell can be efficiently detected, infected and non-infected EBV cell subsets can be recognized, and typing and function comparison are carried out.

Reconstructed Modified Vaccinia Ankara (rMVA) vectors configured to encode stable Epstein Bar Virus (EBV) glycoproteins gp42, gL, gH, gp350, and gB, compositions comprising the rMVA vectors, vaccines comprising the compositions, and methods of preventing EBV infection by administering the vaccines and eliciting an innate and humoral immune response.

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

The application belongs to the technical field of antibodies, and discloses a monoclonal antibody 5E9 for recognizing human R9AP protein and application thereof. The monoclonal antibody or antigen binding fragment thereof has high affinity to R9AP protein and can significantly inhibit EBV infection on epithelial cells and B cells. The antibody can be used for detecting the presence or level of R9AP protein in a sample, detecting diseases caused by high expression of R9AP, and preventing EB virus infection and / or treating and / or preventing diseases caused by EB virus infection.

The present invention relates to the technical field of antibodies. Disclosed are a monoclonal antibody 5E9 for recognizing a human R9AP and a use thereof. The monoclonal antibody or an antigen-binding fragment thereof has a high affinity to an R9AP and can significantly inhibit the infection of EB virus (EBV) on epithelial cells and B cells. The antibody can be used for detecting the presence or level of the R9AP in a sample, detecting diseases caused by high expression of the R9AP and preventing EBV infections and / or treating and / or preventing diseases caused by EBV infections.

Described herein are compositions and methods for treating or preventing EBV infection in a subject, and treating or preventing a disease or disorder caused by EBV infection in a subject.

Provided are a pharmaceutical composition comprising a delivery vehicle and at least two Epstein-Barr virus (EBV) antigen-encoding messenger ribonucleic acid (mRNA) constructs. Methods of treatment, methods of making, uses of the pharmaceutical composition, and pharmaceutical compositions comprising at least two or more EBV antigens are provided. All contemplate treating and preventing (i.e. reducing the likelihood of a symptom or a severity of a symptom of) EBV infections and EBV-associated diseases, such as infectious mononucleosis, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.

The invention discloses a T cell receptor for specifically recognizing an HLA-A11 restricted EBV LMP2 epitope peptide and application of the T cell receptor. The invention relates to the field of biomedicine, and provides a T cell receptor for recognizing HLA-A11 restrictive LMP2373-381 epitope peptide, which comprises an alpha chain and a beta chain, the amino acid sequence of the CDR3 of the alpha chain is as shown in the 107th to 120th sites of SEQ ID NO: 2; the amino acid sequence of the CDR3 of the beta chain is as shown in 109th to 119th sites of SEQ ID NO: 4. According to the present invention, the TCR specifically recognizes and is combined with the LMP2373-381 epitope peptide / HLA-A11 compound, the corresponding TCR-T cell has the LMP2373-381 epitope peptide dependent human target cell killing ability, and the important application value is provided for the prevention and treatment of EBV infection.

The present disclosure relates to nucleic acids molecules, e.g., self-replicating RNA (srRNA) expressing antigenic determinant(s) derived from Epstein-Barr virus (EBV), recombinant cells and pharmaceutical compositions containing the same, as well as the use of such srRNA molecules, recombinant cells, and compositions for eliciting a pharmacodynamic effect in a subject. Also provided are methods for preventing and / or treating various health conditions associated with EBV infection.